|
Dexamethazone Rx, Injectable, 2 mg x 100 ml |  | 
Reg. $5.90 EACH
| | Product Details: | DEXASONE
Rx
RXV
DEXAMETHASONE INJECTION
2 mg/mL
Solution for intravenous or intramuscular injection
DESCRIPTION
DEXASONE INJECTION 2 mg/mL is a synthetic analogue of prednisolone having similar but more potent anti-inflammatory therapeutic action and diversified hormonal and metabolic effects. Modification of the basic corticoid structure as achieved in DEXASONE INJECTION 2 mg/mL offers enhanced anti-inflammatory effect compared to older corticosteroids. The dosage of DEXASONE INJECTION 2 mg/mL required is markedly lower than that of prednisone and prednisolone.
DEXASONE INJECTION 2 mg/mL is not species-specific; however the veterinarian should read the sections on INDICATIONS DOSAGE SIDE EFFECTS CONTRAINDICATIONS PRECAUTIONS and WARNINGS before this drug is used.
DEXASONE INJECTION 2 mg/mL is intended for intravenous or intramuscular administration. Each mL contains 2 mg dexamethasone 500 mg polyethylene glycol 400 9 mg benzyl alcohol 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives 4.75% alcohol HCl to adjust pH to approximately 4.9 water for injection q.s.
EXPERIMENTAL STUDIES
Experimental animal studies on dexamethasone have revealed that it possesses greater anti-inflammatory activity than many steroids. Veterinary clinical evidence indicates dexamethasone has approximately twenty times the anti-inflammatory activity of prednisolone and seventy to eighty times that of hydrocortisone. Thymus involution studies show dexamethasone possesses twenty-five times the activity of prednisolone. In reference to mineralocorticoid activity dexamethasone does not cause significant sodium or water retention. Metabolic balance studies show that animals on controlled and limited protein intake will exhibit nitrogen losses on exceedingly high dosages.
INDICATIONS
DEXASONE INJECTION 2 mg/mL is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine.
As supportive therapy DEXASONE INJECTION 2 mg/mL may be used in the management of various rheumatic allergic dermatologic and other diseases known to be responsive to anti-inflammatory corticosteroids. DEXASONE INJECTION 2 mg/mL may be used intravenously as supportive therapy when an immediate hormonal response is required.
Bovine Ketosis
DEXASONE INJECTION 2 mg/mL is offered for the treatment of primary ketosis. The gluconeogenic effects of DEXASONE INJECTION 2 mg/mL when administered intramuscularly are generally noted within the first 6 to 12 hours. When DEXASONE INJECTION 2 mg/mL is used intravenously the effects may be noted sooner. Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. Acetone bodies are reduced to normal concentrations usually within 24 hours. The physical attitude of animals treated with DEXASONE INJECTION 2 mg/mL brightens and appetite improves usually within 12 hours. Milk production which is suppressed as a compensatory reaction in this condition begins to increase. In some instances it may even surpass previous peaks. The recovery process usually takes from 3 to 7 days.
Supportive Therapy
DEXASONE INJECTION 2 mg/mL may be used as supportive therapy in mastitis metritis traumatic gastritis and pyelonephritis while appropriate primary therapy is administered. In these cases the corticosteroid combats accompanying stress and enhances the feeling of general well-being.
DEXASONE INJECTION 2 mg/mL may also be used as supportive therapy in inflammatory conditions such as arthritic conditions snake bite acute mastitis shipping fever pneumonia laminitis and retained placenta.
Equine
DEXASONE INJECTION 2 mg/mL is indicated for the treatment of acute musculoskeletal inflammations such as bursitis carpitis osselets tendonitis myositis and sprains. If boney changes exist in any of these conditions joints or accessory structures responses to DEXASONE INJECTION 2 mg/mL cannot be expected. In addition DEXASONE INJECTION 2 mg/mL may be used as supportive therapy in fatigue heat exhaustion influenza laminitis and retained placenta provided that the primary cause is determined and corrected.
ADMINISTRATION AND DOSAGE
Therapy with DEXASONE INJECTION 2 mg/mL as with any other potent corticosteroid should be individualized according to the severity of the condition being treated anticipated duration of steroid therapy and the animal’s threshold or tolerance for steroid excess.
Treatment may be changed over to DEXASONE INJECTION 2 mg/mL from any other glucocorticoid with proper reduction or adjustment of dosage.
Bovine - DEXASONE INJECTION 2 mg/mL - 5 to 20 mg intravenously or intramuscularly.
Dexamethasone Powder may be administered or the parenteral dose repeated as needed.
Equine - DEXASONE INJECTION 2 mg/mL - 2.5 to 5 mg intravenously or intramuscularly.
Dexamethasone Powder may be administered or the parenteral dose repeated as needed.
CONTRAINDICATIONS
Except for emergency therapy do not use in animals with chronic nephritis and hypercorticalism (Cushing’s syndrome). Existence of congestive heart failure diabetes and osteoporosis are relative contraindications. Do not use in viral infections during the viremic stage.
PRECAUTIONS
Animals receiving DEXASONE INJECTION 2 mg/mL should be under close observation. Because of the anti-inflammatory action of corticosteroids signs of infection may be masked and it may be necessary to stop treatment until a further diagnosis is made. Overdosage of some glucocorticoids may result in sodium retention fluid retention potassium loss and weight gain.
DEXASONE INJECTION 2 mg/mL may be administered to animals with acute or chronic bacterial infections providing the infections are controlled with appropriate antibiotics or chemotherapeutic agents.
Doses greater than those recommended in horses may produce a transient drowsiness or lethargy in some horses. The lethargy usually abates in 24 hours.
Use of corticosteroids depending on dose duration and specific steroid may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments therapy with a rapid acting corticosteroid should be considered in unusually stressful situations.
WARNINGS
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia fetal death retained placenta and metritis.
Additionally corticosteroids administered to dogs rabbits and rodents during pregnancy have produced cleft palate. Other congenital anomalies including deformed forelegs phocomelia and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.
A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.
SIDE EFFECTS
Side effects such as SAP and SGPT enzyme elevations weight loss anorexia polydipsia and polyuria have occurred following the use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs and cats.
Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.
Corticosteroids reportedly cause laminitis in horses.
HOW SUPPLIED
DEXASONE INJECTION 2 mg/mL 100 mL multiple dose vial.
Store between 2° and 30°C (36° and 86°F).
For Animal Use Only
Prescription items are NON-RETURNABLE and NON-REFUNDABLE. | | Pet Medications>Pet Prescription Medications D-L
|
|
|
|
